Insurer-pharmacy benefit manager (PBM) firms control most of the Medicare Part D market, steering patients to their ...

The Federal Trade Commission published a second interim staff report this week on the prescription drug middleman industry, which ...

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of ...

CVS Health's poor 2024 performance could be turning around in 2025 with a new CEO and potential rebound, despite challenges.

UnitedHealth Group (UNH) stock ends a turbulent year with a quarterly revenue miss amid regulatory challenges and public ...

In an investor call, Andrew Witty promised full transparency and 100% pass-through rebates for prescription drugs by 2028.

Wedmont Private Capital lessened its holdings in shares of CVS Health Co. (NYSE:CVS – Free Report) by 21.5% in the fourth ...

Walgreens Boots Alliance (WBA) stands at a pivotal moment as 2025 begins. It is drawing intense investor scrutiny after ...

Bernstein analyst Lance Wilkes maintained a Hold rating on CVS Health (CVS – Research Report) yesterday and set a price target of $52.00. The ...

The largest pharmacy-benefit managers hiked the prices of dozens of drugs dispensed through their own pharmacies, according ...

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future ...

Canandaigua National Bank & Trust Co. raised its stake in The Cigna Group (NYSE:CI – Free Report) by 24.1% during the fourth ...